
Mohit Narang, MD
Advertisement
Articles by Mohit Narang, MD


Switching patients with chronic lymphocytic leukemia (CLL) from ibrutinib to zanubrutinib has led to fewer cardiac adverse effects and a reduced workload for Mohit Narang, MD, managing partner at Maryland Oncology Hematology.

Mohit Narang, MD, explains why he switches patients with chronic lymphocytic leukemia (CLL) to the second-generation Bruton tyrosine kinase inhibitor.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Elinzanetant Shows Consistent Efficacy, Safety, and Sleep Benefits Across Studies
2
Tirzepatide Plus Hormone Therapy Boosts Weight Loss in Menopause: Regina Castaneda, MD
3
Digital, Blood-Based Innovations Transform Alzheimer Disease Detection: Ken Cohen, MD, FACP
4
Revumenib Granted FDA Approval for R/R NPM1-Mutated AML
5




